Risk of Infection in Patients with Spondyloarthritis and Ankylosing Spondylitis Receiving Antitumor Necrosis Factor Therapy: A Meta-analysis of Randomized Controlled Trials

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2017 Oct 19

PMID 29042938

Citations 13

Authors

Zhigao Xu

Peipei Xu

Wei Fan

Gui Yang

June Wang

Qingyuan Cheng

Mingxia Yu

Affiliations

Soon will be listed here.

Abstract

Antitumor necrosis factor (TNF) agents have been widely used for the treatment of spondyloarthritis (SpA) and ankylosing spondylitis (AS). However, these agents may increase the risk of infection due to suppressing the immune response. The present meta-analysis was performed to systematically investigate the risk of overall infection, serious infection and tuberculosis in patients with SpA and AS treated with anti-TNF agents. Medline, Embase and the Cochrane library were searched for randomized controlled trials (RCTs) published between January 1998 and December 2015 about infection in patients with SpA receiving anti-TNF therapy. Data were pooled to obtain relative risks (RRs) along with their 95% confidence intervals (CIs). A total of 25 RCTs investigating SpA, including 12 investigating AS specifically, were eligible for the meta-analysis. Similar risks of overall infection were reported in patients with SpA (RR, 1.03; 95% CI, 0.92-1.15) and AS (RR, 1.06; 95% CI, 0.91-1.24) treated with anti-TNF agents. The RR of serious infection for patients with SpA or AS receiving anti-TNF therapy compared with a placebo was 1.27 (95% CI, 0.67-2.38) and 1.57 (95% CI, 0.63-3.91), respectively. In addition, 4 RCTs with outcomes of tuberculosis in patients with SpA receiving anti-TNF agents were identified, all in infliximab-treated patients (RR, 2.52; 95% CI, 0.53-12.09). However, due to the limited number of RCTs, this finding should be interpreted with caution. The present meta-analysis did not find any significantly increased risk of infection associated with anti-TNF therapy in patients with SpA or AS. However, due to short duration of follow-up in the RCTs and the rarity of serious infections and tuberculosis, patients treated with anti-TNF agents still should be closely monitored in clinical practice.

Citing Articles

Applications of single-cell RNA sequencing in rheumatoid arthritis.

Figueiredo M Front Immunol. 2024; 15:1491318.

PMID: 39600707 PMC: 11588722. DOI: 10.3389/fimmu.2024.1491318.

Factors associated with cause-specific discontinuation of long-term anti-tumor necrosis factor agent use in patients with ankylosing spondylitis: a retrospective cohort study.

Nam B, Choi N, Koo B, Kim J, Kim T BMC Rheumatol. 2024; 8(1):39.

PMID: 39215338 PMC: 11363619. DOI: 10.1186/s41927-024-00410-w.

Management of Specific Clinical Profiles in Axial Spondyloarthritis: An Expert's Document Based on a Systematic Literature Review and Extended Delphi Process.

Garcia-Vicuna R, Juanola X, Navarro-Compan V, Moreno-Ramos M, Castillo-Gallego C, Moreno M Rheumatol Ther. 2023; 10(5):1215-1240.

PMID: 37450194 PMC: 10468481. DOI: 10.1007/s40744-023-00575-9.

Adalimumab (Humira®) Induced Recurrent Peritonsillar Abscess in A Patient Received Three Different Anti-TNF Therapies: A Case Report.

Vural S, Kusdogan M, Kaya H, Ikiz V, Albayrak L Indian J Otolaryngol Head Neck Surg. 2023; 75(2):1013-1015.

PMID: 37274971 PMC: 10235369. DOI: 10.1007/s12070-022-03203-0.

Adverse events of tumor necrosis factor alpha inhibitors for the treatment of ankylosing spondylitis: A meta-analysis of randomized, placebo-controlled trials.

Feng H, Zhao Y, Kuang W, Dai Y, Cen X, Qin F Front Pharmacol. 2023; 14:1084614.

PMID: 36865909 PMC: 9972296. DOI: 10.3389/fphar.2023.1084614.

References

Knobloch K, Yoon U, Vogt P . Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg. 2010; 39(2):91-2. DOI: 10.1016/j.jcms.2010.11.001. View

Solomon D, Lunt M, Schneeweiss S . The risk of infection associated with tumor necrosis factor alpha antagonists: making sense of epidemiologic evidence. Arthritis Rheum. 2008; 58(4):919-28. DOI: 10.1002/art.23396. View

Mok C, Li O, Chan K, Ho L, Hui P . Effect of golimumab and pamidronate on clinical efficacy and MRI inflammation in axial spondyloarthritis: a 48-week open randomized trial. Scand J Rheumatol. 2015; 44(6):480-6. DOI: 10.3109/03009742.2015.1038300. View

Paramarta J, De Rycke L, Heijda T, Ambarus C, Vos K, Dinant H . Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis. Ann Rheum Dis. 2012; 72(11):1793-9. DOI: 10.1136/annrheumdis-2012-202245. View

Baranauskaite A, Raffayova H, Kungurov N, Kubanova A, Venalis A, Helmle L . Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2011; 71(4):541-8. PMC: 3298666. DOI: 10.1136/ard.2011.152223. View

Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L . Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003; 48(6):1667-75. DOI: 10.1002/art.11017. View

Iseman M, Fischer A . Tumor necrosis factor-alpha at the intersection of mycobacterial immunity and pathogenesis: an important new address in medicine. Clin Infect Dis. 2008; 46(11):1741-2. DOI: 10.1086/587990. View

Sieper J, Kivitz A, van Tubergen A, Deodhar A, Coteur G, Woltering F . Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2015; 67(10):1475-80. PMC: 5054930. DOI: 10.1002/acr.22594. View

Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou C . The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2010; 70(1):25-31. DOI: 10.1136/ard.2010.133645. View

10.

Davis Jr J, van der Heijde D, Braun J, Dougados M, Cush J, Clegg D . Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003; 48(11):3230-6. DOI: 10.1002/art.11325. View

11.

Lateef O, Shakoor N, Balk R . Methotrexate pulmonary toxicity. Expert Opin Drug Saf. 2005; 4(4):723-30. DOI: 10.1517/14740338.4.4.723. View

12.

Dougados M, Combe B, Braun J, Landewe R, Sibilia J, Cantagrel A . A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis. 2010; 69(8):1430-5. DOI: 10.1136/ard.2009.121533. View

13.

Mease P, Gladman D, Ritchlin C, Ruderman E, Steinfeld S, Choy E . Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52(10):3279-89. DOI: 10.1002/art.21306. View

14.

Gomez-Reino J, Carmona L, Descalzo M . Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007; 57(5):756-61. DOI: 10.1002/art.22768. View

15.

Mease P, Fleischmann R, Deodhar A, Wollenhaupt J, Khraishi M, Kielar D . Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2013; 73(1):48-55. PMC: 3888622. DOI: 10.1136/annrheumdis-2013-203696. View

16.

Guellec D, Nocturne G, Tatar Z, Pham T, Sellam J, Cantagrel A . Should non-steroidal anti-inflammatory drugs be used continuously in ankylosing spondylitis?. Joint Bone Spine. 2014; 81(4):308-12. DOI: 10.1016/j.jbspin.2014.01.003. View

17.

Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, OConnor P . Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis. 2005; 64(11):1568-75. PMC: 1755262. DOI: 10.1136/ard.2004.022582. View

18.

van der Heijde D, Da Silva J, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X . Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis. 2006; 65(12):1572-7. PMC: 1798458. DOI: 10.1136/ard.2006.056747. View

19.

Gorman J, Sack K, Davis Jr J . Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002; 346(18):1349-56. DOI: 10.1056/NEJMoa012664. View

20.

van der Heijde D, Kivitz A, Schiff M, Sieper J, Dijkmans B, Braun J . Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006; 54(7):2136-46. DOI: 10.1002/art.21913. View